MPC-8 Serum anti-zinc finger FYVE domain-containing protein 21 (ZFYVE21) autoantibody as a novel biomarker for oligodendroglioma IDH-mutant and 1p/19q co-deletion

Abstract Background: Glioma is one of the most challenging diseases to cure, and it would be beneficial to discover new serum biomarkers for early diagnosis. Moreover, zinc finger FYVE domain-containing protein 21 (ZFYVE21) was a regulator of tumor invasion and migration. In this study, we examined...

Full description

Saved in:
Bibliographic Details
Published in:Neuro-oncology advances 2021-12, Vol.3 (Supplement_6), p.vi17-vi17
Main Authors: Matsutani, Tomoo, Boshi, Zhang, Hirono, Seiichiro, Nagane, Motoo, Yoshino, Atsuo, Tanaka, Shouta, Ishikawa, Eiichi, Fukami, Shinziro, Yamaguchi, Fumio, Li, Shuyang, Watanabe, Yousuke, Kobayashi, Masayoshi, Ikegami, Shiro, Hiwasa, Takaki, Iwadate, Yasuo
Format: Article
Language:English
Subjects:
Supplement Abstracts
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background: Glioma is one of the most challenging diseases to cure, and it would be beneficial to discover new serum biomarkers for early diagnosis. Moreover, zinc finger FYVE domain-containing protein 21 (ZFYVE21) was a regulator of tumor invasion and migration. In this study, we examined the levels of serum anti-ZFYVE21 antibodies in patients with glioma. Methods: This is a multicenter observational prospective study to discover a novel serum autologous antibody marker. We analyzed 286 pre-surgically collected sera of CNS tumors and compared them to healthy donors(HD). Bacterially expressed glutathione-S-transferase-fused ZFYVE21 protein was purified, and its antibody levels were measured by amplified luminescent proximity homogeneous assay-linked immunosorbent assay (AlphaLISA). Results: The anti-ZFYVE21 antibody levels were significantly elevated in patients with gliomas (P
ISSN:2632-2498
2632-2498
DOI:10.1093/noajnl/vdab159.063